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Mammalian phenylalanine hydroxylase (PAH) has a potential allosteric regu-
latory binding site for L-phenylalanine (L-Phe), in addition to its catalytic site.
This arrangement is supported by a crystal structure of a homodimeric trun-
cated form of the regulatory domain of human PAH (hPAH-RD1–118/19–118)
[Patel D et al. (2016) Sci Rep doi: 10.1038/srep23748]. In this study, a fusion
protein of the domain (MBP-(pepXa)-hPAH-RD
1–120) was overexpressed and
recovered in a metastable and soluble state, which allowed the isolation of a
dimeric and a monomeric fusion protein. When cleaved from MBP, hPAH-
RD forms aggregates which are stereospecifically inhibited by L-Phe
(> 95%) at low physiological concentrations. Aggregation of the cleaved
dimer of the mutant form hPAH-G46S-RD was not inhibited by
L-Phe, which is compatible with structurally/conformationally changed bab-
bab ACT domain folds in the mutant.
Enzyme kinetic and biophysical studies of the full-length
rat and human phenylalanine hydroxylase (r/hPAH)
homotetramer have indicated that its catalytic activa-
tion by L-phenylalanine (L-Phe) involves a slow (s-to-
min timescale) global conformational change, preceding
the chemical steps characteristic of a hysteretic enzyme
[1,2]. Mammalian PAH shows a complex activation
mechanism. Based on indirect experimental evidence,
two main working models have been proposed: (i) bind-
ing of L-Phe to a putative allosteric site in the N-term-
inal regulatory domain (RD) as well as to the catalytic
site [3–8], and (ii) cooperative binding of L-Phe (nH
about 2) at the catalytic site which represents the site of
initiation (‘epicentre’) for the conformational transition
in the activation process [9–14]. The first model was
originally based on indirect enzyme kinetic and
biophysical studies on the rPAH tetramer and truncated
RD constructs, but has lately gained further support
from the determination of the X-ray crystal structure of
the full-length ligand-free and autoinhibited rat and
human enzyme at low resolution (PDB ID: 5DEN at
2.9 A [15] and PDB ID: 5EGQ at 3.6 A) [8]) and the
high resolution crystal structure (PDB ID: 5FII at
1.8 A) of a homodimeric truncated form of the human
RD (hPAH-RD) [16]. Representing the key finding of
this study, the structure revealed two L-Phe molecules
bound to a homodimer at the interphase of the two
b1a1b2b3a2b4 ACT domain folds along the plane of the
twofold axis [16]. However, in the absence of L-Phe, the
overexpressed construct aggregated.
The missense mutation p.G46S in hPAH (Fig. 1) is
associated with a severe form of phenylketonuria and
Abbreviations
ANS, 8-anilino-1-naphthalenesulfonic acid; MBP, maltose-binding protein; nH, Hill coefficient; PAH, phenylalanine hydroxylase; RD, regulatory
domain; SAXS, small angle X-ray scattering; SEC, size-exclusion chromatography.
195FEBS Open Bio 7 (2017) 195–203 ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use,
distribution and reproduction in any medium, provided the original work is properly cited.
generates a misfolded protein which is rapidly degraded
on expression in HEK293 cells [17]. The crystal struc-
ture of the wt-hPAH-RD has shown that L-Phe binding
includes the sequence region E43xVxAL in the two pro-
tomers [16], and it was therefore of great interest to test
the effect of a G?S substitution on the L-Phe binding
to the b1a1b2b3a2b4 ACT domain folds in the hPAH-
G46S-RD mutant form. Since a previous attempt has
failed to express this mutant form in a nonaggregated
and soluble form [16], we here overexpressed it as a
fusion protein (MBP-(pep)Xa-hPAH-RD). This change
in the RD construct results in a stabilization of both
the wt and mutant forms of the RD protein in a meta-
stable and soluble state, and allows the isolation of a
dimeric and a monomeric fusion protein. When cleaved
by factor Xa, the maltose-binding protein (MBP)-free
wt-RD of both forms undergoes aggregation, which is
stereospecifically prevented by L-Phe. Thus, the sub-
strate stabilizes a dimer of the RD. 8-Anilino-1-
naphthalenesulfonic acid (ANS) binding studies with
the dimeric wt fusion protein confirmed the stereospeci-
fic binding of L-Phe in a physiological concentration
range. With reference to the behaviour of the wt-
hPAH-RD, it is shown that L-Phe does not bind and
stabilize the mutant form hPAH-G46S-RD due to a
structural/conformational change in its wt-binding site
involving residues E43xVxAL in the dimeric
b1a1b2b3a2b4 ACT domain folds.
Materials and methods
TB1 cells, the prokaryotic expression vector pMAL-c2/
pMAL-hPAH and the amylose resin were obtained from
New England Biolabs (Ipswich, MA, USA). The restriction
protease factor Xa was obtained from Protein Engineering
Technology ApS (Aarhus, Denmark). ANS were obtained
from Sigma-Aldrich (Oslo, Norway).
Site-specific mutagenesis
The wt-RD (pMAL-hPAH-RD1–120) and its G46S mutant
form (pMAL-hPAH-G46S-RD1–120) were obtained by
introducing a stop signal in codon 121 of hPAH by site-
directed mutagenesis (QuikChange II; Stratagene, Santa
Clara, CA, USA), using the wt-pMAL-hPAH [18] and
pMAL-G46S-hPAH constructs [17] as templates respec-
tively. Primers 5ʹ-GACACAGTGCCCTGGTAACCAA
GAACCATTCAAGAGC-3ʹ (forward) and 5ʹ-GCTCTTG
AATGGTTCTTGGTTACCAGGGCACTGTGTC-3ʹ (re-
verse) used for mutagenesis were provided by Eurogentec
(Seraing, Belgium; the mismatch nucleotides are shown in
bold). The authenticity of the mutagenesis was verified by
DNA sequencing as described previously [17].
Overexpression and isolation of fusion proteins
The wt and G46S mutant forms of hPAH-RD were overex-
pressed in Escherichia coli as fusion proteins (MBP-
(pep)Xa-hPAH-RD) [18]. The bacteria were grown at 37 °C
and the induction by 1 mM isopropyl-thio-b-D-galactoside
was performed for 8 h at 28 °C. The fusion proteins were
purified by affinity chromatography (amylose resin) and
centrifuged in a TL-100 Ultracentrifuge (Beckman, India-
napolis, IN, USA) for 20 min at 50 000 g before size-exclu-
sion chromatography (SEC), as described earlier [18]. SEC
was performed as described in the legend to Fig. 2. The
Fig. 1. 3D structure of PAH protomer (rPAH1–429), sequence and
secondary structure assignment of the N-terminal regulatory
domain (RD) of hPAH and the localization/interactions of the G46
residue in the RD. (A) Ribbon representation of the regulatory/
catalytic domain crystal structure of rPAH (PDB ID: 1PHZ at the
highest resolution (2.2 A) for this structure) in the monomeric form
with the RD shown in green, the catalytic domain in red, the iron
as a yellow sphere and G46 in stick model (pointed arrow). (B)
Sequence of the N-terminal regulatory domain of hPAH (SwissProt
P00439) with elements of secondary structure (determined from
the coordinates of PDB ID: 1PHZ with the program DSSP [26]
indicated above the sequence and numbered sequentially from the
N terminus [4]. Figure (A) was created using PyMOL, version 1.1
(DeLano Scientific) [27].
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dimeric and monomeric protein fractions were concentrated
by Centriplus 30 filter (Amicon, Darmstadt, Germany). The
concentration of purified fusion proteins was measured using
the absorption coefficient A280 (1 mgmL1cm1) = 1.34. A
colorimetric method [19] was in some cases also used to mea-
sure enzyme concentrations, with bovine serum albumin as
the standard.
Cleavage of MBP-hPAH-RD fusion proteins and
assay of self-association by light scattering
Before cleavage of the MBP-hPAH-RD fusion proteins by
factor Xa they were centrifuged at 210 000 g for 15 min at
4 °C. In the standard assay at 20 mM Na-Hepes, 0.1 M
NaCl, pH 7.0 and 25 °C the concentration of the fusion
protein was 0.74 mgmL1, and the concentration of factor
Xa was adjusted to give a final ratio (by weight) of 1 : 150
relative to the fusion protein. Self-association (aggregation)
of the factor Xa-released RD was followed in real-time by
light scattering, as measured by the increase in the apparent
absorbance at 350 nm A0350 = log [Io/(Ip + fId)], using an
Agilent 8453 Diode Array Spectrophotometer (Matriks AS,
Oslo, Norway) with a Peltier temperature control unit as
previously described [20]. The change in light scattering was
expressed as DA0350 by subtracting the background absor-
bance in the absence of the added factor Xa. The rate of
oligomerization was expressed as DA0350/Dt and was
obtained from the slope of the linear growth phase of each
light scattering curve. In each experiment a parallel time-
course cleavage analysis was conducted to rule out any effect
of the cleavage rate.
In order to study the inhibitory effect of L-Phe/D-Phe on
aggregation of MBP-free wt-hPAH-RD and its mutant
form, the fusion proteins were preincubated for 5 min at
standard assay conditions with L-Phe (0–1 mM) before the
cleavage was initiated with factor Xa. The inhibition of
aggregation was analysed by the SigmaPlot Technical
Graphing Software (Alfasoft AS, Lillestrøm, Norway). The
Hill plot analyses for the inhibition was performed as pre-
viously described [21], and the Hill coefficient (nH) was cal-
culated by fitting the data into the linear form of the Hill
plot equation: log[vi/(vovi)] = nHlog[L]  nHlog[k]. [L]0.5
represents the concentration of L-Phe at 50% inhibition.
SDS/PAGE analyses
The purification of the fusion proteins and the efficiency of
its cleavage by factor Xa, was analysed by SDS/PAGE in a
10% (w/v) polyacrylamide gel [22]. The gels were stained
by Coomassie Brilliant Blue R-250, scanned using Versa-
Doc 4000 (Bio-Rad, Hercules, CA, USA) and quantifica-
tion of the protein bands was carried out by using the
Quantity One 1-D Analysis Software (Bio-Rad).
ANS-binding assay
Fluorescence-based ANS binding studies were performed as
described [23]. The fluorescence emission spectra were
recorded between 400 and 600 nm (6-nm slit width) at
25 °C using an excitation wavelength of 385 nm (6-nm slit
width) on a Perkin-Elmer LS-50B luminescence spectrome-
ter (Perkin-Elmer, Waltham, MA, USA) and by averaging
four scans.
Negative staining of wt-hPAH-RD oligomers and
electron microscopy
For negative staining EM of wt-hPAH-RD oligomers, For-
mvar-coated 200 mesh nickel grids (Electron Microscopy
Sciences, Hatfield, PA, USA) were used. The grids were
further coated with carbon, stored dust-free in Petri dishes
kept at low humidity and glow-discharged for 15 s prior to
use. Negative staining was carried out by first applying
5 lL of a protein solution on the specimen grid. Following
absorption for 60 s, the sample drop was removed by blot-
ting with filter paper, and the grid was stained twice with
2% (w/v) aqueous uranyl acetate. After application, the
first drop of stain (10 lL) was blotted off immediately,
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Fig. 2. Size-exclusion chromatography of the MBP-hPAH-RD1–120
construct. Peak 1, higher order oligomeric forms (eluted at the void
volume); peak 2, dimeric form (~ 156 kDa); peak 3, monomeric
form (~ 65 kDa), and peak 4, degradation products (~ 39 kDa). The
molecular mass of the enzyme forms were estimated using the
elution position of standard molecular mass markers as a reference
(not shown). 10.7 mg of fusion protein were applied to the column.
The chromatography was performed on a HiLoad Superdex 200 HR
column (1.6 cm 9 60 cm) from Amersham Biosciences (GE
Healthcare, Oslo, Norway), equilibrated and eluted with 20 mM Na-
Hepes, 0.2 M NaCl, pH 7.0 at a flow rate of 0.38 mLmin1 at 4 °C
and detection was at 280 nm. The inset represents a SDS/PAGE
analysis demonstrating the purity of the fusion proteins after two
steps of purification. Lane M, low molecular mass standard (106.5,
97.6, 50.2, 36.9 and 28.9 kDa); lane 2, dimeric form (peak 2); lane
3, monomeric form (peak 3) and lane 4, degradation products (peak
4) after the size-exclusion chromatography.
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whereafter a fresh drop of the stain was added to the grid
for 15 s. After final blotting and drying, the specimens were
observed in a Jeol 1230 Electron Microscope (Jeol USA,
Inc., Peabody, MA, USA) operated at 80 kV.
Results
Overexpression and isolation of the wt-MBP-
hPAH-RD fusion proteins
On overexpression of wt-MBP-(pep)Xa-hPAH-RD
1–120
the soluble affinity purified fusion protein was sepa-
rated by SEC into oligomeric forms and some aggre-
gates. The chromatogram of the fusion protein
(10.7 mg; Fig. 2) revealed four peaks, where peak 1
represented minor aggregates eluted at or near the
void volume, while peak 2 and peak 3 represented the
dimeric and monomeric forms respectively. Identical
mobilities were observed for peaks 2 and 3 on SDS/
PAGE (Fig. 2), with an apparent molecular mass of
~ 63 kDa. Peak 4 represents degradation products.
Cleavage of the MBP stabilized wt fusion
proteins
At the standard assay conditions (pH 7.0, 0.1 M NaCl
and 25 °C) the cleavage of the metastable and soluble
wt-MBP-hPAH-RD fusion proteins (~ 0.7 mgmL1)
by factor Xa (5.0 lgmL1) was very similar for the
dimeric and the monomeric fusion protein, with t1/2
(time at 50% cleavage) of ~ 11 min. The presence of
L-Phe had no significant effect on the cleavage of
wt-MBP-hPAH-RD by factor Xa.
Aggregation of wt-hPAH-RD upon cleavage of
dimeric and monomeric MBP fusion proteins and
its stereospecific inhibition by L-Phe
On cleavage of equal amounts (~ 0.7 mgmL1) the
dimeric and monomeric MBP-hPAH-RD fusion pro-
teins by factor Xa (5.0 lgmL1) aggregates are formed
(Fig. 3), with a similar time-course observed for the two
fractions. It includes a delay period (lag phase), and a
growth phase of increasing light scattering (DA0350/
Dt)max of 3.9  0.1 9 103 and 1.3  0.1 9 103
AUmin1, for the dimeric (Fig. 3A) and monomeric
(Fig. 3B) protein fractions respectively. For ultrastruc-
ture of the aggregates and soluble protein (see Fig. 7
below). In the absence of added factor Xa no change in
light scattering was observed for the two fractions
within the time frame of 3 h.
The aggregation of the MBP-free RD is inhibited in
a stereospecific manner by L-Phe; 100 lM L-Phe almost
completely protects against the aggregation, whereas
100 lM D-Phe and other L-amino acids gave no effect
(Fig. 4A). The inhibition revealed a [L]0.5 value of
23.3  0.5 lM L-Phe on cleavage of the dimeric form,
with a positive cooperativity; the Hill coefficient was
calculated to be about 2 (nH = 2.05) (see Materials
and methods section). A similar stereospecificity was
observed on factor Xa cleavage of the monomeric




















Fig. 3. The self-association of hPAH-RD1–120 following cleavage of
dimeric (A) and monomeric (B) MBP fusion proteins by factor Xa,
and the effect of L-Phe. (A) The time-course of the self-association
was followed in real-time by light scattering, as measured by the
increase in the apparent absorbance at 350 nm (DA0350). The data
points correspond to dimeric wt-hPAH1–120 fusion protein following
cleavage by factor Xa in the absence of any added compound (●)
and in the presence of 1 mM L-Phe (▲). (♢) represents dimeric wt-
hPAH1–120 fusion protein in the absence of factor Xa. (B) The time-
course of the self-association in the absence of any added
compound (●) and in the presence of 1 mM L-Phe (▲). (♢)
represents monomeric wt-hPAH1–120 fusion protein in the absence
of factor Xa. The reactions were performed at standard assay
conditions (0.74 mgmL1 fusion protein, 5.0 lgmL1 factor Xa,
20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 and 25 °C). Some data
points were omitted for clarity. Error bars represent mean  SD
(n = 3).
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fraction (data not shown), and the [L]0.5 value for the
inhibition of aggregation was 15.1  2.4 lM L-Phe,
but with a hyperbolic inhibition curve (Fig. 5B).
Binding of ANS to wt-MBP-hPAH-RD before and
after cleavage
8-Anilino-1-naphthalenesulfonic acid is a spectroscopic
probe displaying affinity for hydrophobic clusters
which are not tightly packed in a fully folded
structure, or become exposed in partially unfolded
structures [24]. ANS binds to ligand-free dimeric wt-
MBP-hPAH-RD fusion protein (Fig. 6A), and its fac-
tor Xa cleaved forms (t = 3 h) (Fig. 6B), with an
increase in the fluorescence intensity and a blue shift
(maximum at ~ 478 nm), resulting from the binding.
Identical spectra were obtained in the absence and
presence of 1 mM D-Phe, whereas L-Phe revealed a
concentration-dependent decrease, in a physiological
concentration range, and a red shift of the fluorescence
spectra (Fig. 6A,B). A much smaller effect of L-Phe on
Time (min)



























Fig. 4. (A) The stereospecific inhibition of the self-association of
hPAH-RD1–120 by phenylalanine. The time-course of the self-
association of hPAH-RD1–120 protein following cleavage of
themdimeric fusion protein by factor Xa in the absence (●) and
presence of 100 lM L-Phe (▲) or 100 lM D-Phe (M). (B) The self-
association of dimeric hPAH-RD1–120 and its G46S mutant form and
the effect of L-Phe. The time-course of the self-association of
hPAH-RD1–120 dimeric protein following cleavage of the fusion
protein by factor Xa in the absence (●) and presence of 150 lM L-
Phe (○); hPAH-G46S-RD1–120 dimer fusion protein following
cleavage by factor Xa in the absence (■) and presence of 150 lM
L-Phe (□). Some data points were omitted for clarity. The assays
were performed at standard assay conditions and error bars
represent mean  SD, n = 3 independent experiments.























































Fig. 5. The effect of L-Phe concentration on the inhibition of the self-
association (aggregation) of dimeric (A) and monomeric (B) MBP
fusion protein hPAH-RD1–120. The inhibitory effect of L-Phe on the
aggregation was assayed at standard conditions (0.74 mgmL1
fusion protein, 5.0 lgmL1 factor Xa, 20 mM Na-Hepes, 0.1 M NaCl,
pH 7.0 and 25 °C) with varying concentrations of L-Phe (01 mM)
and the rate of forming higher order oligomers (DA0350/Dt) was
obtained from the slope of the linear growth phase of each light
scattering curve. The L-Phe dose-dependent inhibition curves of the
aggregation were generated by nonlinear regression analysis of the
experimental data using the four parameter logistic equation (see
Materials and methods). The insets represent the data obtained at
the concentration range 0250 lM L-Phe.
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ANS binding was observed for the monomeric fusion
protein fraction (Fig. 6C,D), which is slightly contami-
nated by the dimeric form, due to its chromatograpgic
tailing. The MBP fusion partner alone has a negligible
contribution to the ANS fluorescence, and there was
no additional effect of L-Phe (Fig. 6A).
L-Phe does not protect against aggregation of
the hPAH-G46S-RD mutant form
When the mutant protein hPAH-G46S-RD is overex-
pressed in E. coli, mainly insoluble protein is
recovered [17]. In contrast, here the fusion protein
MBP-hPAH-G46S-RD was isolated as a metastable
and soluble protein (Fig. 4B). On SEC chromatogra-
phy only the dimeric form was recovered at suffi-
ciently high yield for further analyses (Fig. 4B), and
it revealed the same electrophoretic mobility on
SDS/PAGE as the wt dimeric RD. In the absence of
added factor Xa no change in light scattering was
observed within 3 h. Upon cleavage by factor Xa,
the MBP-free G46S-RD aggregated, but in this case
no protection against aggregation by L-Phe was
observed (Fig. 4B) at concentrations up to 1 mM
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Fig. 6. The binding of ANS to dimeric fusion protein MBP-hPAH-RD1–120. Briefly, 1.3 lM MBP-hPAH-RD was incubated with 60 lM ANS in
20 mM Na-Hepes, 0.1 M NaCl, pH 7.0 at room temperature for 5 min in the dark. (A) ANS fluorescence emission spectra of the fusion
protein in the absence of ligand (trace 1), with 100 lM L-Phe (trace 3), 1 mM L-Phe (trace 4), and 1 mM D-Phe (trace 2). The MBP protein
was used as a control in the absence (trace 5) and in the presence of 1 mM L-Phe (trace 6) and the emission spectrum of buffer with ANS
is shown (trace 7). (B) ANS fluorescence emission spectra observed after cleavage of the dimeric MBP-hPAH-RD1–120 fusion protein by
factor Xa (t = 3 h) in the absence of ligand (trace 1), with 100 lM L-Phe (trace 4), 1 mM L-Phe (trace 5), 100 lM D-Phe (trace 2), 1 mM D-Phe
(trace 3) and the emission spectrum of buffer with ANS (trace 6). (C) ANS fluorescence emission spectra of the monomeric wt-hPAH1–120
fusion protein in the absence of ligand (trace 1), with 100 lM L-Phe (trace 3), 1 mM L-Phe (trace 4), 1 mM D-Phe (trace 2) and the emission
spectrum of buffer with ANS (trace 5). (D) ANS fluorescence emission spectra observed after cleavage of the monomeric wt-hPAH1–120
fusion protein by factor Xa (t = 3 h) in the absence of ligand (trace 1), with 100 lM L-Phe (trace 3), 1 mM L-Phe (trace 4), 1 mM D-Phe (trace
2) and the emission spectrum of buffer with ANS (trace 5). The excitation wavelength was 385 nm.
200 FEBS Open Bio 7 (2017) 195–203 ª 2016 The Authors. Published by FEBS Press and John Wiley & Sons Ltd.
p.G46S mutation and no binding of L-Phe to PAH-RD J. Leandro et al.
that inhibited wt-RD dimer aggregation by > 95%
(Fig. 5A).
Ultrastructure of wt-hPAH-RD oligomers
In order to get information on the fine structure of the
wt-hPAH-RD1–120 protein and its higher order aggre-
gates that are both formed on factor Xa cleavage of
the fusion protein, negative staining EM was per-
formed on aliquots removed at different times during
the cleavage reaction. EM micrographs corresponding
to the final time point (t = 180 min) with complete
cleavage (Fig. 7) revealed that while the self-associa-
tion of the wt protein generated some unstructured
higher order aggregates, the main field is dominated
by small structures with a dimeric appearance.
Discussion
A recent SAXS analysis of the rat PAH homotetramer
lead to the proposal that the L-Phe-induced activation
and associated conformational changes involve dimer-
ization of the RDs, creating two binding sites for
L-Phe [8]. These binding sites have later been defined
in a high resolution (1.8 A) structure of a homod-
imeric truncated form of hPAH-RD in complex with
L-Phe [16]. In the same study on size-exclusion chro-
matography of hPAH-RD1–118 and hPAH-RD19–118,
both constructs are reported to elute as a mixed popu-
lation of monomer and higher order aggregates. How-
ever, the addition of L-Phe stabilizes the constructs
and reduces their aggregation tendency, likely through
domain dimerization [16]. In the present study, it is
found that expressing a similar construct of the human
RD as a MBP fusion protein (MBP-hPAH-RD) pre-
serves the recombinant protein in a metastable confor-
mational state, which protects against aggregation
since MBP functions as a molecular chaperone [25].
The dimeric and monomeric fractions, isolated by SEC
in an apparent dimer↔monomer equilibrium (Fig. 2),
both form aggregates when MBP is cleaved off by fac-
tor Xa (Fig. 3). The aggregation of the MBP-free
hPAH-RDs is prevented by L-Phe (> 95%) for both
forms (Fig. 5), and the effect is stereospecific (Fig. 4a).
Half-maximal inhibition ([L]0.5) was obtained at
23.3  0.5 lM L-Phe (cleaved dimeric fraction) and
15.1  2.4 lM L-Phe (cleaved monomeric fraction).
These numbers for the apparent affinity of L-Phe bind-
ing to human RD are in good agreement with the
Kd-value of 15.2  1.1 lM (n = 0.9  0.1 sites per
monomer) measured for the rat RD dimer by ITC [8]).
In both the rat and human dimeric forms, a positive
cooperativity of L-Phe binding was observed, with a
calculated Hill coefficient (nH) value of ~ 2.
That L-Phe also binds to the MBP-hPAH-RD dimer
before factor Xa cleavage was shown by its reduction
of the ANS fluorescence enhancement observed upon
the binding of the hydrophobic fluorescence probe to
the fusion protein (Fig. 6A). Also, in this assay sys-
tem, the measured responses to L-Phe were stereospeci-
fic (Figs 4A and 6A), with L-Phe being present in a
physiological concentration range (Fig. 6). This finding
indicates that the dimer formation of the fusion pro-
tein is based on an interaction between the RDs of
two protomers, capable of binding L-Phe.
In contrast to wt-MBP-hPAH-RD, a structurally/
conformationally variant mutant form (MBP-hPAH-
G46S-RD, Fig. 1A) revealed no protection against
aggregation by L-Phe upon cleavage by factor Xa of
its dimeric form. The lack of stabilizing effect indicates
that the binding site in the RD is sensitive to the con-
formation of its b1a1b2b3a2b4 sandwich fold. In the
crystal structure of the hPAH-RD [16] L-Phe binding
includes the sequence region E43xVxAL in the two
protomers. The residue G46 is positioned at the entry
of a-helix 1 (A47-E57) in a five residue (L41-G46) loop
structure (loop 1), linking b-strand 1 and a-helix 1.
Fig. 7. Electron micrograph of MBP-free wt-hPAH-RD1–120
[complete cleavage of its MBP fusion protein by factor Xa
(t = 3 h)]. The proteins were negatively stained with aqueous
uranyl acetate and imaged in the JEOL 1230 Transmission Electron
Microscope operated at 80 kV. Structures with a dimeric
appearence, corresponding to about 20% of the small-sized
structures are circled and also highlighted in the inset. The open
arrows indicate larger protein aggregates. Scale bar: 500 nm.
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The substitution G46?S is predicted to promote a
N-terminal extension of a-helix 1 by four residues, or
one turn [20].
In conclusion, we report a method for the prepara-
tion of highly pure, metastable and soluble
dimeric↔monomeric forms of the human N-terminal
RD as a MBP fusion protein. Our data support previ-
ous biochemical and biophysical studies on isolated
recombinant rat and human RDs, that is: (i) L-Phe
binds to a recombinant RD dimer in a physiological
concentration range and stabilizes the structure; and
(ii) L-Phe binds with relatively high affinity and with a
positive cooperativity (nH about 2). In addition, our
data demonstrate that the binding is stereospecific for
L-Phe, and that the RD mutation G46S prevents the
binding of L-Phe and its protection against aggregation
of MBP-free RD. This effect is explained by a struc-
tural/conformational change in its wt-binding site
involving the residues E43xVxAL in dimeric
b1a1b2b3a2b4 ACT domain folds. Overall, our data are
compatible with an emerging model of the full-length
PAH in which L-Phe binding to dimerized RDs may
be involved in the complex substrate activation process
of this multidomain enzyme. However, in contrast to
the catalytic domain [13] there is no crystal structure
available for the substrate-bound form of the homote-
tramer [8,15].
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